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Abstract
This report illustrates a new strategy in designing a T1-T2 dual-modal magnetic resonance imaging
(MRI)-visible vector for siRNA delivery and MRI. Hydrophobic gadolinium embedded iron oxide
(GdIO) nanocrystals are self-assembled into nanoclusters in water phase with the help of stearic
acid modified low molecular weight polyethylenimine (stPEI). The resulting water-dispersible
GdIO-stPEI nanoclusters possess good stability, monodispersity with narrow size distribution and
competitive T1-T2 dual-modal MR imaging properties. The nanocomposite system is capable of
binding and delivering siR-NA for knockdown of a gene of interest while maintaining magnetic
properties and biocompatibility. This new gadolinium embedded iron oxide nanocluster provides
an important platform for safe and efficient gene delivery with non-invasive T1-T2 dual-modal
MRI monitoring capability.
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Since Fire et al.1 reported the mediator role of double-stranded RNA molecules (dsRNA) in
gene silencing in Caenorhabditis elegans, great efforts have been made to use RNA
interference (RNAi) as a potential therapeutic strategy for genetic diseases2–4. However, one
of the impediments to successful RNAi is the inefficient delivery of siRNA to target tissues
due to the inherent poor stability and negative charge of exogenous naked siRNA. The
development of safe and effective carriers for these genetic molecules is still a desired goal
for the widespread use of RNAi in the clinic5–8. The viral vector-mediated gene therapy has
been demonstrated to be effective but the biological safety is still the major concern for
clinical translation9–11. As an alternative method, non-viral carrier systems based on the
cationic polymers have been introduced. Generally, the non-viral carriers can condense
nucleic acids in vitro primarily through electrostatic interactions and effective delivery into
cells with a number of potential advantages, such as good stability, low immunogenicity and
extensive modified pontentials to meet the requirement of targeted delivery, multimodal
imaging, hyperthermia, and so on12–17.
Another need in the development of gene delivery system is the real-time monitoring of
distribution of genetic molecules after delivery and transfection, which would be useful for
optimizing the gene therapy protocol. Magnetic resonance imaging (MRI) is a widely used
diagnostic tool with excellent anatomical details with or without the application of contrast
agents such as superparamagnetic iron oxide nanoparticles (SPIOs)18–20. The popularity of
SPIOs is mainly attributed to their unique features - good biocompatibility, magnetic
properties, high surface area-to-volume ratio, and adaptable surface for bioagent
attachment21. Recently, we and others have reported the application of SPIOs as MRI
visible nanocarriers for drug and gene delivery22–27. However, the significant drawbacks of
SPIOs as T2 MRI probes are magnetic susceptibility artifacts and negative contrast, which
limit their clinical applications especially when hemorrhages in tissues are present.
In this study, we report a novel approach to form a biocompatible, efficient, and T1-T2 dual-
modal MRI-visualized nanocomposite for siRNA delivery and monitoring (Fig. 1). The
nanocomposites were constructed with a shell of stearic acid-modified low molecular weight
polyethylenimine (stPEI) and a core of gadolinium embedded iron oxide (GdIO)
nanoparticles through self-assembly. It was found that the nanovector (abbreviated as GdIO-
stPEI) with a controlled clustering structure possess competitive T1-T2 dual-modal MR
imaging properties. We further found through agarose gel electrophoresis, toxicity and MRI
studies, that GdIO-stPEI nanoclusters are capable of stable binding, protecting, and
delivering siRNA for gene silencing while maintaining magnetic properties and high
biocompatibility. Based on these systematic studies, we demonstrated that GdIO-stPEI
nanoclusters possess low cytotoxicity, high siRNA transfer efficiency and T1-T2 dual-modal
MR imaging properties, promising them as a safe and efficient avenue for gene therapy and
MRI.
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Oleic acid (tech. 90%), and 1-octadecene (tech. 90%) were purchased from Acros.
Gadolinium(III) chloride hexahydrate (99.99%) and methyl acrylate (99%, stable with ca. 15
ppm 4-methoxyphenol) were purchased from Alfa Aesar. Sodium oleate, iron chlorides and
other reagents were purchased from Sinopharm Chemical Reagent Co. Ltd. All chemicals
were used as received without further purification.
PC-3 human prostate cancer cell line and 293T human embryonic kidney cell line were
purchased from the American Type Culture Collection (ATCC). HCT-116 human colorectal
carcinoma cell line which stablely express firefly luciferase (HCT-116) was from the School
of Life Sciences, Xiamen University. Cell culture medium DMEM and fetal calf serum
(FBS) were purchased from Hyclone. All cells were cultured in the DMEM medium
supplmented with 10% FBS, plus 50 units/ml penicillin and 50 μg/ml streptomycin, in a
humidity incubator with 5% CO2 at 37 °C. Cells were passaged or used for experiments
when reaching 80–90% confluency.
Preparation of GdIO-stPEI nanoparticles
The GdIO nanoparticles were synthesized following a previously reported procedure28.
Briefly, iron oleate, gadolinium oleate, and oleic acid were mixed in a three neck bottle flask
containing 1-octadecene. The solution was heated to reflux for 2 h under inert atmosphere.
After cooling to room temperature, the solution was added with isopropanol to precipitate
the nanoparticles. The precipitation was redissovled with hexane and washed twice, the final
product was collected by centrifugation and dispersed in chloroform for further use.
For the preparation of GdIO-stPEI nanoparticles, 5 mg stPEI was mixed with the as-
prepared GdIO nanoparticles (10 mg) in chloroform (2 mL). The organic solution was
slowly added into distilled water (4 mL) under vigorous sonication, the mixture was further
shaken for overnight to obtain a transparent solution. The residual chloroform was removed
via rotary evaporation, and the water-soluble GdIO-stPEI nanoparticles were stored in buffer
solution for further use. The preparation of GdIO-DMSA nanoparticles was followed by the
reported method28 for comparison purpose.
Characterizations of GdIO-stPEI nanoparticles
The transmission electron microscope (TEM) images were recorded on JEM-2100
microscope (JEOL, Japan) at an accelerating voltage of 200 kV. The dynamic light
scattering (DLS) and zeta potential measurements of GdIO-stPEI nanoparticles in buffer
solution (pH 6.0–8.0) were performed on a Zetasizer (Malvern Zetasizer Nano system)
operated at 298 K. The MRI experiments were tested at a 0.5 T NMR120-Analyst NMR
Analyzing & Imaging system (Niumag Corporation, Shanghai, China).
MR imaging capacity of GdIO-stPEI nanoparticles
GdIO-stPEI (or GdIO-DMSA) nanoclusters of various metal concentrations containing 1%
agar were prepared for MRI phantom study, ranging from 25 to 200 μM for Fe, and 2 to 16
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μM for Gd ions. The longitudinal and transverse relaxation times were measured at 305 K,
and the relaxation rates (r1 and r2) were obtained from the slopes of 1/T1 or 1/T2 to the
coresponding concertrations. T2-weighted and T1-weighted MR images of GdIO-stPEI
nanoclusters and GdIO-DMSA were acquired using multiple spin-echo (MSE) sequence
under the following parameters: TR/TE = 2000/40 ms (T2), TR/TE = 300/10 ms (T1), 128 ×
256 matrices, Repetition times: 4.
Agarose gel retardation assay of GdIO-stPEIs/siRNA complexes
GdIO-stPEI/siRNA complexes were analyzed by gel electrophoresis. The gels were
prepared as 2% agarose (Biowest, Spain) in TAE buffer containing 0.5 μg/mL ethidium
bromide. 100 ng of siRNA or plasmid DNA (pll3.7, 7.4 Kb) were mixed with different doses
of GdIO-stPEI nanoclusters and incubated at room temperature for 20 min. After that, these
samples were mixed with appropriate amount of loading buffer and pippetted into agarose
gel. Gel electrophoresis was carried out at 100 V for 30 min and subsequently imaged in the
Bio-Rad ChemiDoc XRS Imaging Systems (Bio-Rad life science, the U.S.A).
Cytotoxicity assay
The cytotoxicity of GdIO-stPEI complexes was evaluated following the standard 3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay protocol. Briefly,
2,000 cells suspended in 80 μL medium were seeded into each well of the 96-well plate.
After 24 h of incubation, GdIO-stPEI mixed with 100 ng siRNA at a range of N/P ratios in
20 μL cell culture medium were added into wells. After further incubation for 72 h, 10 μL
MTT (5 mg/mL) solution was added into each well, and incubated for another 3 h. Finally,
the solution was removed, and 100 μL dimethyl sulfoxide (DMSO) was added into each well
to dissolve the formazan crystals. The absorption of DMSO solution at 570 nm was
measured using a microplate spectrophotometer. The relative cell viability was calculated as
the following formulation: The relative cell viability (%) = the Abs. of treatment group / the
Abs. of control group × 100%.
Cell transfection
Confocal laser scanning microscopy (CLSM) was used to assess the intracellular uptake of
siRNA. HCT-116 cells were seeded into the 35 mm culture dish with glass bottom and
transfected with GdIO-stPEI/FAM-labeled siRNA complex as mentioned above. Then, cells
were fixed with 4% paraformalclehyde and observed with the Leica TCS SP5 CLSM
imaging system (Leica, Germany) with an inverted confocal microscope.
To further assess the gene silencing efficiency, the bioluminescence imaging (BLI) signal
intensity of HCT-116 cells was measured after transfection29. HCT-116 cells were
transfected with Silencer® Firefly Luciferase (GL2 + GL3) siRNA (Ambion). At 48 h post-
transfection, cells were trypsinized and 40,000 cells in 100 μL medium were pippeted into
96-well plate and imaged using the IVIS-lumina II system (Caliper Life Sciences) after D-
luciferin (20 μL per well of 3 mg/mL stock) addition.
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Cell MR imaging study
HCT-116 cells were transfected with GdIO-stPEI/siRNA at the N/P ratios of 60 and 80 as
mentioned above. Cells without transfection were set as a control. At 4 h post-transfection,
cells were washed 3 times with PBS solution to eliminate excess amount of nanoparticles
and harvested by trypsinization. After being fixed in 4% paraformalclehyde, cells were
dispersed in 20 μL PBS solution and mixed with 20 μL 2% low melting agarose in
eppendorf tube. T2-weighted and T1-weighted MR images of the cells were acquired using
the following parameters: TR/TE = 2000/30 ms (T2), TR/TE = 300/10 ms (T1), 256 × 256
matrices, Repetition times: 16.
Statistical analysis
The data was statistically analyzed by Student’s t-test and p < 0.05 was considered
statistically significant.
Results
Preparation and characterization of GdIO-stPEI nanoparticles
The GdIO nanoparticles were synthesized by a thermal decomposition process, following
our previously reported procedure28. The as-prepared GdIO nanoparticles showed good
monodispersity with diameters of 13.5 ± 1.7 nm, presented by transmission electron
microscopy (TEM) (Fig. S1). We also analyzed the molar ratio of Fe and Gd in the GdIO
nanoparticles by inductively coupled plasma atomic emission spectroscopy (ICP-AES),
which showed similar molar ratio (Fe/Gd = 12.65:1) to that reported previously, giving it
great potential to be an efficient T1-T2 dual modal contrast agent for MRI. In order to
rationally design GdIO-based gene delivery nanovectors, surface modification processes are
necessary to stabilize GdIO to create strong interactions for loading and releasing nucleic
acid molecules. Herein, we employed amphiphilic stearic acid-modified low molecular
weight polyethylenimine stPEI (PEI MW600) to obtain biocompatible GdIO nanoparticles
with high siRNA binding capability. The alkyl chain of steric acid of stPEI assembled
spontaneously with oleic acid on the surface of GdIO nanoparticles, through hydrophobic-
hydrophobic interactions in water solution. The resulting nanoclusters were denoted as
GdIO-stPEI with plenty of stPEI exposed on the surface, which meets well the requirements
to load negatively charged siRNA in an efficient manner. The TEM images showed that the
diameter of GdIO-stPEI nanoparticles was 78.9 ± 8.5 nm (Fig. 2A), with an organic layer
about 3–4 nm thick (Fig. 2A, inset). TEM studies also showed that each nanocomposite is a
cluster of a few closely-packed GdIO nanoparticles.
To further evaluate the hydrodynamic diameter (HD) of GdIO- stPEI nanoparticles, we used
DLS instrument to measure the nanoparticle size and distribution of GdIO-stPEI
nanoparticles in buffer solutions with various pH values, ranging from 6.0 to 8.0. As shown
in Fig. 2B, the measured HD of GdIO-stPEI nanoclusters were much larger than that shown
in TEM images even for the smallest HD of 118.7 nm in pH 6.0 buffer solution, which may
be attributed to the highly hydrated PEI layer in water. The hydration of PEI appears to be
pH dependent, thus the HD of GdIO-stPEI nanocluaters increased from 118.7 nm at pH =
6.0 to 153.2 nm at pH = 7.0. Further increase of pH did not have much effect on the HD of
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GdIO-stPEI nanocluaters. This phenomenon can be explained by acid-base neutralization
theory and electrostatic repulsion theory. Under acidic environment, the acidulated amine
groups on the surface of GdIO-stPEI possess strong electrostatic repulsion effect between
each other, which can reduce the probability of collision. Therefore, the measured HD of
GdIO-stPEI at low pH values tends to be smaller than that at high pH values because the
DLS measurement relies mainly on the dynamic behaviors of colloidal particles. On the
contrary, the zeta potential of GdIO-stPEI nanoparticles was inversely related to pH values
in the range of pH 6.0 to 7.0, and fluctuated moderately even by the pH value up to 8.0. This
also matches the acid-base neutralization theory well that the acidulated amine groups on the
surface of GdIO-stPEI nanoparticles contribute to the zeta potential values in acidic
environment.
MRI relaxivity measurement and phantom study
To validate the T1-T2 dual-modal contrast capability of GdIO-stPEI nanoclusters and the
feasibility of stPEI coating strategy, the relaxivity and phantom measurements were
performed on a 0.5 T MRI machine. By forming nanoaggregates, the GdIO-stPEI
nanoparticles showed a greatly enhanced r2 value of 181.49 ± 1.57 mM−1·s−1 (Fig. 3),
compared to the GdIO-DMSA nanoparticles measured under the same conditions (r2: 131.37
± 2.08 mM−1·s−1). This phenomenon can be attributed to the enhanced local magnetic field
of the multi-domain GdIO-stPEI nanostructures through strong exchange coupling effect,
which further accelerated the dephasing process of surrounding protons. On the other hand,
the r1 value of GdIO-stPEI nanoclusters was represented as 61.67 ± 0.82 mM−1·s−1, similar
to that of GdIO- DMSA nanoparticles (r1: 63.25 ± 2.86 mM−1·s−1). In general, there are two
major factors in this system which may influence the longitudinal relaxation time (r1 value):
the integrated enchancement of multi-domain structure, and the proton-exchange efficiency
of the surrounding water to the surface of magnetic nanoparticles. It is noteworthy that the
GdIO-stPEI nanostructures possess strong integration effect of r1 relaxation enhancement,
which would positively affect the r1 value. Whereas the stPEI coating layer would decrease
the proton-exchanging efficiency, leading to the decline of the r1 value. Overall, the GdIO-
stPEI nanoclusters exhibited competitive T1-T2 dual-modal contrast effect as shown in Fig.
3B, which may provide accurate MR imaging and detection in vitro, especially in cellular or
molecular MRI studies.
Assessment of the siRNA binding ability
In our previous work30, SPIO packaged stPEI have been demonstrated to bind the big
molecular DNA (like plasmid) effectively. However, siRNA is more difficult to be delivered
due to the difference in molecular size and spatial conformation. Generally, siRNA of 19–23
bp in length is a topologically rigid molecule and thus it is difficult to be condensed and
packed tightly by cationic agents, while plasmid DNA molecules can be more easily packed
and delivered by cationic agents. Additionally, siRNA adopts an A-conformation of narrow
major groove and shallow minor groove as opposed to the B conformation of DNA, which is
also difficult for cationic vectors binding31. In a word, a good vector for plasmid DNA does
not necessarily mean it is good for siRNA15.
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To assess the siRNA binding ability of GdIO-stPEI nanoclusters, siRNA against luciferase
were incubated with GdIO-stPEI at differernt N/P ratios and analyzed by agarose gel
electrophoresis. As shown in Fig. 4A, naked siRNA was mobile in the electric field, while in
the GdIO-stPEI/siRNA complexes, the negative charges of siRNA were efficiently
neutralized by the positively charged GdIO-stPEI and the mobility of siRNA was
completely inhibited at the N/P ratio over 10, which was close to the binding capacity of
plasmid DNA pll3.7 (MW 7.6 Kb) at the comparative test (Fig. 4B). A successful gene
delivery carrier should also protect the cargo from enzymatic degradation during
transfection. To assess such a qualification, different N/P ratios of GdIO-stPEI/siRNA
complexes were incubated with FBS at 37°C overnight and the residual siRNA was detected
by agarose electrophoresis. GdIO-stPEI/siRNA complexes were obviously much more
stable than the naked siRNA after the serum treatment, and the protection effect was
enhanced with more GdIO-stPEI used (data not shown).
Cell viability study
Low cytotoxicity is a prerequisite of nanovectors for siRNA delivery. The in vitro
cytotoxicity of the GdIO-stPEI/siRNA complexes was evaluated 72 h post-transfection
using the MTT assay by measuring the metabolic activity of the cells. As shown in Fig. 5A,
GdIO-stPEI complexes showed little cytotoxicity in the designated concentration range, with
more than 80% of cell viability at the N/P ratio up to 60 in 293T cells and up to 120 in PC-3
cells. Generally, the low molecular weight of PEI (such as PEI600) has lower cytotoxicity
than the high molecular weight analogs (such as PEI25K, Fig. S2)32, but stPEI/siRNA
complexes are generally more cytotoxic than GdIO-stPEI/siRNA complexes at high N/P
ratios (Fig. 5B, C). This could be attributable to the much higher positive charge of stPEI/
siRNA complexes (29.4 ± 9.03 mV) than that of GdIO-stPEI/siRNA complexes (8.13 ± 4.78
mV), as the cytotoxicity of cationic polymers is thought to be a result of membrane
damaging effects by the positive charge and reduction of the positive charge would improve
biocompatibility27, 33.
In vitro siRNA transfection study
In this work, the siRNA transfection efficiency of the GdIO-stPEI nanoclusters was assessed
by the cellular internalization of FAM-labeled siRNA and the inhibition of luciferase
activity in the HCT-116 human colon carcinom cells. By considering the requirements for
siRNA binding, protection, cytotoxicity and cellular MRI, we set N/P ratio at 60 for the cell
experiments. As shown in Fig. 6, FAM-labeled siRNA molecules were successfully taken up
by the cells after being mixed with GdIO-stPEI or stPEI as strong green fluorescence was
observed inside the cells. Additionally, the siRNA carrier should deliver siRNA into cells
but release them in the cytoplasm in which the RNAi complex form and function15, 34. As
shown in this work, FAM-labeled siRNA were exclusively observed in the cytoplasm,
which suggests that GdIO-stPEI nanoclusters are effective in steering the intracellular
distribution of siRNA. To further evaluate the potential of GdIO-stPEI nanoclusters as
siRNA carrier, firefly luciferase targeted siRNA were transfected with GdIO-stPEI NPs and
gene expression was assessed by the measurement of enzyme activity. As shown in Fig. 7,
the bioluminescence of cells was significantly inhibited after treatment with GdIO-stPEI/
siRNA complexes, and the inhibition effect was similar to that of the commercially available
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Lipofectamine™ 2000. All these data demonstrated that GdIO-stPEI nanoclusters mediated
effective siRNA delivery into cells and resulted in remarkably efficient gene silencing.
Cellular MR imaging study
To evaluate the feasibility of using T1-T2 dual-modal MRI to track the delivery of
Luciferase siRNA, the MR signal intensity of HCT-116mi cells treated with GdIO-stPEI/
siRNA complexes was measured on a 0.5 T MRI machine. The T1- and T2-weighted MR
images were acquired respectively as shown in Fig. 8. As expected, the T1 MR images
displayed concentration dependent MR signal intensity. For T2 MR images, the MR signal
intensity was inversely-related to concentrations comparing to that of T1 MR images. These
mutual-confirming results demonstrated great potency for GdIO-stPEI nanoclusters as T1-T2
dual-modal contrast agent for cellular MRI.
Conclusions
In summary, we have demonstrated a novel dual-modal MRI visible siRNA delivery system,
with good cytocompatibility and high siRNA delivery efficiency, which suggests that GdIO-
stPEI nanoclusters are suitable for intracellular delivery of siRNA for potential therapy. By
taking the advantages of T1-T2 dual-modal contrast imaging property, this work
demonstrates a promising theranostic system, and sets the foundation of combining the MR
imaging modality of GdIO and therapeutic modality of siRNA. Because of the plenty of
amine groups at the end of PEI, this design platform can be functionalized with other
interesting molecules (e.g., targeting molecules, fluorescent dyes) for multifunctional
applications. Additionally, this approach may provide a general strategy for delivering
various types of lipophilic drugs into cells, and is of great importance in biomedical research
and disease therapy. Since many magnetic nanoparticles have been used in clinical settings
for many years, there is a high potential that GdIO-stPEI nanoclusters will be applicable in
clinical gene therapy in the future.
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Schematic illustration of the preparation of GdIO-stPEI/siRNA complexes and function.
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Characterization of GdIO-stPEI nanoparticles. (A) TEM and HRTEM (inset) images of
GdIO-stPEI. (B) Hydrodynamic diameter (left) and zeta potential (right) profiles of GdIO-
stPEI nanoparticles at different pH values.
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Relaxivity measurement and MRI phantom study of GdIO-stPEI nanoparticles. (A) T1 and
T2 relaxivity profiles of GdIO-stPEI nanoparticles. (B) T1 and T2 MRI phantom images of
GdIO-stPEI nanoparticles with various Fe and Gd concentrations.
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Electrophoretic retardation analysis of (A) GdIO-stPEI/siRNA or (B) plasmid DNA
complexes. GdIO-stPEI displayed the same binding capicity to siRNA and the big molecular
DNA. M: DNA marker DL15000 (Takara).
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Cellular toxicity of GdIO-stPEI complexes. (A) The viability of 293T and PC-3 cells after
treatment with various concentrations of GdIO-stPEI. (B) and (C) Comparation of
cytotoxicity of GdIO-stPEI/siRNA and stPEI/siRNA at the N/P ratio of 120. At such a high
N/P ratio, stPEI induced cell contraction and then death, while cells expsoed to GdIO-stPEI
remained viable and intact cell morphology, which suggests a better biological compatibility
of GdIO-stPEI over stPEI.
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Confocal microscopic images of siRNA cellular uptake by HCT-16 cells, siRNA was mixed
with GdIO-stPEI or stPEI at the N/P ratio of 60 and incubated with cells for 6 h.
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siRNA transfection effect assessment with the firefly luciferase activity assay. The relative
expression of luciferase protein was assessed by measuring the light produced in the
reaction. **: p < 0.01 compared with the control group.
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In vitro MR imaging study with transfected HCT-116 cells.
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